Sale of IgDraSol - Additional Information (Details) - USD ($)		1 Months Ended	3 Months Ended	12 Months Ended
	Jul. 08, 2015	Jul. 31, 2015	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Schedule Of Gain Loss On Investments Including Marketable Securities And Investments Held At Cost Income Statement Reported Amounts Summary [Line Items]
Gain on sale of IgDraSol, net				$ 69,274,000	$ 0	$ 0
Relative fair value allocation of goodwill attributable to IgDraSol upon sale to NantPharma				(3,415,000)
IgDraSol, Inc. [Member]
Schedule Of Gain Loss On Investments Including Marketable Securities And Investments Held At Cost Income Statement Reported Amounts Summary [Line Items]
Milestones payments received			$ 90,050,000
Shares issued to former stockholders		1,306,272
Gain on sale of IgDraSol, net			69,274,000
Relative fair value allocation of goodwill attributable to IgDraSol upon sale to NantPharma			$ 3,415,000
Pre-tax gain (loss) on sale of IgDraSol				$ (8,375,000)	$ (13,489,000)	$ (2,388,000)
NantPharma [Member] | Upfront Payment [Member]
Schedule Of Gain Loss On Investments Including Marketable Securities And Investments Held At Cost Income Statement Reported Amounts Summary [Line Items]
Milestones payments received	$ 90,050,000
Milestones payments obligated to fund joint venture	60,000,000
NantPharma [Member] | Regulatory Milestone Payments [Member] | Maximum [Member]
Schedule Of Gain Loss On Investments Including Marketable Securities And Investments Held At Cost Income Statement Reported Amounts Summary [Line Items]
Milestones payments received	620,000,000
NantPharma [Member] | Sales Milestone Payments [Member] | Maximum [Member]
Schedule Of Gain Loss On Investments Including Marketable Securities And Investments Held At Cost Income Statement Reported Amounts Summary [Line Items]
Milestones payments received	$ 600,000,000